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The EGFR family members sustain the neoplastic phenotype
of ALKþ lung adenocarcinoma via EGR1
C Voena1,2, F Di Giacomo1,2,8, E Panizza1,2,8, L D’Amico1,2, FE Boccalatte1,2, E Pellegrino1,2, M Todaro1,2, D Recupero2,
F Tabbo`2, C Ambrogio1,2, C Martinengo1,2, L Bonello1,2, R Pulito3, J Hamm3, R Chiarle1,2, M Cheng4, B Ruggeri4,
E Medico5,6 and G Inghirami1,2,7
In non-small cell lung cancer (NSCLC), receptor tyrosine kinases (RTKs) stand out among causal dominant oncogenes, and the
ablation of RTK signaling has emerged as a novel tailored therapeutic strategy. Nonetheless, long-term RTK inhibition leads
invariably to acquired resistance, tumor recurrence and metastatic dissemination. In ALKþ cell lines, inhibition of ALK signaling was
associated with coactivation of several RTKs, whose pharmacological suppression reverted the partial resistance to ALK blockade.
Remarkably, ERBB2 signaling synergized with ALK and contributed to the neoplastic phenotype. Moreover, the engagement of
wild-type epidermal growth factor receptor or MET receptors could sustain cell viability through early growth response 1 (EGR1)
and/or Erk1/2; Akt activation and EGR1 overexpression prevented cell death induced by combined ALK/RTK inhibition. Membrane
expression of ERBB2 in a subset of primary naive ALKþ NSCLC could be relevant in the clinical arena. Our data demonstrate that
the neoplastic phenotype of ALK-driven NSCLC relays ‘ab initio’ on the concomitant activation of multiple RTK signals via autocrine/
paracrine regulatory loops. These findings suggest that molecular and functional signatures are required in de novo lung cancer
patients for the design of efficacious and multi-targeted ‘patient-specific’ therapies.
Oncogenesis (2013) 2, e43; doi:10.1038/oncsis.2013.7; published online 8 April 2013
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INTRODUCTION
Lung tumors are the most common form of cancer (12.3%), with
1.1 million deaths worldwide, accounting for 17.8% of all cancer
fatalities. Despite major diagnostic improvements and novel
tailored compounds, 90% of lung cancer patients die within 1–2
years from diagnosis.1
Molecular studies have showed that nearly all lung cancers
display multiple genetic defects2–4 and the abnormal activation
of kinases is widely recognized as a frequent tumorigenic
mechanism in non-small cell lung cancer (NSCLC).3,5–7 Epidermal
growth factor receptor (EGFR) and its ligands are commonly dere-
gulated, leading to receptor tyrosine kinase (RTK) phosphorylation
fostering cell proliferation, inhibition of apoptosis and enhancing
pro-angiogenesis and invasion signals.8 Tumor-acquired EGFR
mutations have been documented in 5–10% of Caucasian NSCLC,
often associated to unique clinico-pathologic features.9 Specific
genetic alterations of KRAS, BRAF, PIK3CA, ALK and, more recently,
ROS and RET have been described in well-defined subsets of
NSCLC.6,7,10,11 These lesions represent ‘driver mutations’, as lung
cancers depend on their constitutive activation.12,13 Thus,
molecular screening of NSCLC is mandatory to guide the most
appropriate therapies (that is, small molecule kinase
inhibitors).14,15 Cancers harboring the same genetic alterations,
however, respond differently to molecular targeted therapies,
suggesting coexisting mutations or coactivation of other TKs.16
Finally, although molecularly targeted therapies (that is, gefitinib
or erlotinib for EGFR and crizotinib for ALK fusions) are effective in
NSCLC, intrinsic or acquired resistances inevitably lead to
recurrence and/or metastatic dissemination. This is the case of
MET activation/amplification,17,18 or acquired somatic mutations
of EGFR (T790M)19 or ALK fusions (G1269A, L1196M and ALK
amplification).20–22
Chromosomal translocations involving the ALK gene have been
described in 6% of NSCLC, where ALK is most frequently fused to
the echinoderm microtubule-associated protein-like 4 (EML4).23 As
described for other ALK chimera, the EML4–ALK fusions contain a
dimerization domain, which forces the ligand-independent
oligomerization of the catalytic domain of ALK, resulting in its
constitutive kinase activation. ALK fusions are oncogenic ‘drivers’
imposing a full cellular transformation, and are required for the
maintenance of the neoplastic phenotype.24,25 Nevertheless, data
from phase I clinical trials of ALK-rearranged NSCLC treated with
the ALK inhibitor (ALKi) crizotinib showed an overall response rate
ofB60%, suggesting that synergizing or overcoming mechanisms
may occur.26,27
Here we provide novel insights into ALK-driven transformation
in NSCLC, demonstrating that tumor maintenance and survival of
ALKþ NSCLC cells, before any therapeutic selection, relay on the
concomitant activation of multiple EGFR family RTKs. These data
support the hypothesis that the degree of ALK addiction might
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differ ‘ab initio’ among different ALKþ NSCLC patients and its
identification should provide a novel rationale for the design of
efficacious ‘patient-specific’ treatments.
RESULTS
ALK fusion proteins transform human immortalized lung epithelial
cells and sustain the tumor phenotype of ALKþ NSCLC cell in vitro
and in vivo
As it has been described that transformation of lung epithelial
cells requires many hits, and that several oncogenes are unable to
fully transform these elements, even in the presence of
deregulated p53 and Rb-1 pathways, we assessed the transform-
ing potential of ALK chimera in immortalized cell line (NuLi-1)
derived from human normal airway epithelium. NuLi-1 cells were
transduced with EML4–ALK variant 1 (EML4/exon13–ALK/exon20)
or TFG–ALK constructs. Forced expression of EML4–ALK and
TFG–ALK fusions led to constitutive phosphorylation of STAT3,
SHC and Shp2 (Figure 1a), and imposed a transformed phenotype
(Figure 1b).
To evaluate the biological effects of EML4–ALK, we transduced
ALK-positive cell lines (H3122 and H2228) with ALK-specific
inducible short hairpin RNA (shA5) or control short hairpin
RNA (shA5M) lentivirus cassettes. Alternatively, cells (ALKþ and
ALK (H1395)) were treated with ALK-selective inhibitors (CEP-
14083 and CEP-26939, from Cephalon/Teva, West Chester, PA,
USA).28,29 ALK inhibition led to a significant decrease in the
phosphorylation of known ALK downstream targets (STAT3, Erk1/
2, Shp2 and Akt; Supplementary Figure 1A).24 As expected,
ablation of ALK signaling was associated with growth impairment
(Figure 1c and Supplementary Figure 1B) and a very high rate of
apoptosis for the H3122 cells (Figure 1d and Supplementary
Figure 1C). Consistently, in vivo treatment with CEP-26939 led to a
decreased number of proliferating cells, without any significant
loss of ALK protein expression (Supplementary Figures 1D and E),
and to tumor mass regression. This treatment, however, did not
result in tumor eradication (Supplementary Figure 1F).
Signaling through the EGFR–TK proteins contributes to the
survival and growth of ALKþ NSCLC cells
On the basis of our previous phosphoproteomics findings30 and
on the different degree of ALK oncogenic addiction of
ALKþ NSCLC lines and primary tumors,31 we investigated the
association of anti-ALKi29 with small anti-TK drugs currently into
the clinics. Combined treatment of H2228 cells with ALKi and with
the EGFR inhibitor gefitinib, or with an anti-EGFR monoclonal
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Figure 1. Lung-associated ALK fusion proteins transform human immortalized lung epithelial cells and are fundamental for the maintenance
of the tumor phenotype. (a) NuLi-1 cells were infected with retrovirus expressing different ALK fusion proteins and were collected 96 h after
transduction. NPM–ALK and the kinase-dead (EML4–ALKK589R or TFG–ALKK231R) fusion proteins were used as controls. Total cell lysates were
immunoblotted with the indicated antibodies. (b) NuLi-1 cells transduced with the indicated constructs were plated in soft agar and cultured
for 3 weeks. The histograms represent the average numbers of colonies grown in soft agar from the indicated cells and constructs. The
number of colonies obtained in TFG–ALK, EML4–ALK or NPM–ALK transduced cells is significantly higher as compared with untransduced cells
or to cells transduced with the kinase-dead constructs (*Po0.0005; left panel). Colonies show green fluorescent protein (GFP) positivity (right
panel). The number of colonies is normalized to the percentage of infection for every single construct. Cells were plated in triplicate. Results
are representative of two different experiments. (c) H2228 TTA A5 and H2228 TTA A5M were cocultured with the untransduced counterpart,
respectively, and grown in the presence of 1 mg/ml doxycycline. GFP expression was quantified at indicated time points by fluorescence-
activated cell sorting (FACS) analysis and normalized against the initial time point (day 0). Results are representative of two different
experiments. (d) H3122, H2228 and H1395 cell lines were treated every 24 h with 300 nM CEP-14083 or CEP-26939. Tetrametylrodamine methyl
ester staining followed by FACS analysis was performed after 48 and 72h of treatment to check the percentage of apoptotic cells. Significance
according to the analysis of variance test corresponded to *Po0.05 and **Po0.005. Results are means of duplicates (s.e.m.), and graphics
show one representative experiment from two independent assays.
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antibody (cetuximab), resulted in increased cell death. Similar
findings were seen in H3122 cells after single anti-ALK treatment
(Figure 2a and Supplementary Figures 2A and B), possibly related
to higher protein expression and phosphorylation status of EGFR
in only H2228 cells (Supplementary Figures 2C and D). Impor-
tantly, H2228 and H3122 cells were both insensitive to single
treatment with gefitinib. As other members of the EGFR family are
associated to RTK inhibitor resistance, we then investigated the
functional role of ERBB2 and ERBB3 in the less-responsive H2228
cells.18,20 We observed a marked presence of ERBB2/ERBB3 and
EGFR/ERBB3 heterodimers in H2228 in the absence of exogenous
stimuli (Supplementary Figure 3A). Moreover, ERBB3 protein/
mRNA levels were upregulated in H2228 when treated with anti-
ALK small molecules (Figure 2b). Interestingly, we detected a
constitutive phosphorylation of ERBB2 that was completely
abrogated upon treatment with lapatinib (Figure 2b and
Supplementary Figure 3B), and the combination of lapatinib with
CEP-28122 suppressed cell growth and significantly reduced the
number of viable cells as compared with CEP-28122 alone
(Figure 2c). In contrast, the combined treatment had no further
effect in H3122 cells (Supplementary Figure 3C). Remarkably, a
significant subset of primary ALKþ NSCLC (12/21, 57%; but ALK
NSCLC 38/180, 21%) shows a strong immunohistochemical
membrane staining for ERBB2 (Figure 2d).
Overall, these data suggest that ALK inhibition might be
overcome by alternative RTK pathways in ALKþ NSCLC cells.
Ligand-mediated activation of tyrosine receptor kinases rescues
ALK kinase inhibition through AKT and Erk1/2 pathways
As EGF can be secreted by lung epithelial cancer and/or
stromal cells, we investigated whether an autocrine–paracrine
EGF-mediated activation of the EGFR signaling in H2228 cells
could explain their partial resistance to ALK inhibition and
overcome ALK inhibition of ALK-sensitive cells. Consistent with
recently published data, upon stimulation with exogenous EGF
the effects associated with the abrogation of the ALK signaling
(CEP-28122) were overcome in both cell lines as documented by
an increased cell viability and growth, which were restored to
baseline levels (Figure 3a and Supplementary Figures 4A and B).
Cells cotreated with gefitinib and/or expressing a mutant form of
the EGFR (T790, data not show) could not be rescued by the
exogenous EGF (Supplementary Figure 4A).20,32
The molecular mechanisms operating in the EGF/EGFR-
mediated rescue were first examined by the phosphorylation
status of ALK and known ALK effectors. These were not affected.
On the contrary, EGF stimulation could sustain the phosphorylated
status of EGFR, Akt and Erk1/2, despite an ALK inhibition
(Figure 3b). Finally, an increased expression of the proapoptotic
protein BIM was seen only with the dual inhibitor cotreatment in
H2228, whereas ALK inhibition alone was sufficient to induce a
significant upregulation of BIM in H3122 (Figure 3b).33 Similar
results were obtained by heregulin stimulation. Upon heregulin
stimulation the phosphorylation of ERBB3, Erk1/2 and Akt
significantly increased (Figure 3c and Supplementary Figure 4B)
and cell viability was rescued despite ALK inhibition (Figure 3d).
As hepatocyte growth factor (HGF)/Met signaling or Met
overamplification can be involved in gefitinib resistance in lung
cancer,18,34 we then explored the effects of HGF. HGF promoted a
moderate proliferation and sustained cell viability upon ALK
inhibition through Erk1/2 and Akt pathways (Supplementary
Figures 5A and B). As expected, crizotinib, a dual ALK–Met
inhibitor, abolished the prosurvival signals triggered by HGF
(Supplementary Figure 5C).
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Figure 2. In H2228, apoptosis is increased by the combined treatment with ALK inhibitors and gefitinib or lapatinib. (a) H2228 cells were
treated in 0.05% FCS with CEP-14083 or CEP-28122 (300 nM), and gefinitib (G; 1 mM) as single agent or in combination. Apoptosis was measured
by tetrametylrodamine methyl ester (TMRM) staining and fluorescence-activated cell sorting (FACS) analysis at the indicated tome points.
*Significance is referred to the corresponding single-agent treatment. (b) H2228 cells were treated with CEP-28122 alone or in combination
with lapatinib (L) or gefitinib (G) in 0.05% FCS for 24 h. Total cell lysates were blotted with the indicated antibodies. (c) H2228 cells were
treated with CEP-28122 alone or in combination with lapatinib in 0.05% FCS. TMRM staining followed by FACS analysis was performed at
indicated times of treatment to check the percentage of apoptotic cells. (d) Primary ALKþ NSCLC were stained with anti-ERBB2 or anti-ALK
antibodies. Shown are two representative cases.
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Figure 3. EGF or Heregulin stimulation rescues ALK-treated NSCLC cells through Erk1/2 and AKT. (a) Cell viability of treated H2228 and H3122
cells with or without EGF stimulation (10 ng/ml) was evaluated with Cell Titer-Glo Luminescent cell viability assay at the indicated time points.
Significances * and ** is referred to the corresponding single-agent treatment. (b) H2228 and H3122 cells were treated for 6 h with 300 nM
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collected. Total cell lysates were blotted with the indicated antibodies. (c,d) H2228 cells were treated with CEP-28122 alone or combined with
gefitinib or lapatinib for 24 h, and with or without Heregulin (HRG) stimulation (50 ng/ml) for 30min and then collected. Total cell lysates were
blotted with the indicated antibodies (c). Cell viability was evaluated as previously described at the indicated time points. Significance
according to Student’s t-test corresponded to *Po0.05 (d). Significances * and ** are referred to the corresponding single treatment without
EGF or Heregulin stimulation. Results are representative of three different experiments.
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Figure 4. Src is a common node downstream of ALK and EGFR signaling pathways in NSCLC ALK-positive cells. (a) H2228 and H3122 cells were
treated with CEP-28122 and with 5 mM SKI-I (S) in 0.05% FCS for 24 h and for 12 h, respectively. Total cell lysates were blotted with the indicated
antibodies. (b–e) H2228 and H3122 cells were treated with CEP-28122 alone or in combination with 5 mM Src kinase inhibitor-1 (SKI-1), and
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viability assay (b, d) and the percentage of apoptotic cells was quantified by tetrametylrodamine methyl ester staining followed by
fluorescence-activated cell sorting analysis (c, e).
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As Src has a pathogenetic role in EGFR-mutated NSLCL35 and is
also a critical interactor in ALKþ anaplastic large cell lymphoma,24
we applied a selective Src kinase inhibitor-1 as a single agent
(Figure 4a) or in combination with CEP-28122. The combined
treatment increased cell death only in H2228 that was partially
rescued by EGF administration (Figures 4b–e). These data suggest
that Src-independent pathways might be active in H2228 cells. On
the contrary, EGF did not restore cell viability of H3122 cells
treated with ALK and Src–TK inhibitor. Similar findings were
observed using dasatinib, a pan Src inhibitor (data not shown).
Early growth response 1 (EGR1) gene is upregulated by active ALK
and EGFR, and promotes survival
To identify ALK cooperating oncogene(s) in H2228 NSCLC cells, we
interrogated their transcriptome before and after TK inhibitor
treatment. Gene expression analysis showed that a single gene,
early growth response 1 (EGR1), was significantly suppressed by
the combined ALK/EGFR treatment (fold-change 42, Po0.001;
Supplementary Figure 6). Quantitative reverse transcription–PCR
confirmed that the loss of ALK signaling or the dual treatment led
to a substantial inhibition of the EGR1 expression (Figure 5a),
whereas gefitinib had no effect. Downregulation of EGR1 could be
inhibited by exogenous EGF that overcame cell death as well
(Supplementary Figure 7A). Moreover, Src inhibition in association
with CEP-28122 strongly reduced the level of expression of EGR1
in both cell lines (Supplementary Figure 7B). Reversely, ectopic
expression of EGR1 in H2228 cells (Supplementary Figure 7C)
prevented cell growth inhibition and cell death via CEP-28122
and/or gefitinib combination (Figures 5b and c). Finally, forced
expression of EGR1 could revert BIM levels to baseline (Figure 5d
and Supplementary Figure 7D), meanwhile knockdown of EGR1 in
H2228 through short hairpin RNA impaired cell growth (data not
shown). Overall, these findings indicate that both ALK and EGFR
signaling are required for EGR1 expression and demonstrated a
central role of this transcription factor in ALKþ NSCLC cells.
To identify EGR1-regulated genes, we investigated the tran-
scriptional profile of H2228 cells stably transduced with EGR1
(EGR1þ ). This revealed a set of 780 genes linked to EGR1 (fold-
change 42, Po0.001). Notably, EGR1 overexpression resulted in
ERBB3 mRNA upregulation that was further increased by ALK
inhibition (Supplementary Figure 8). Expression profiling of
EGR1þ cells treated with ALKi and EGFR–TK inhibitor reported
two clusters of genes behaving independently of ALK inhibition,
as these genes showed a marked up- or downregulation in wild-
type treated cells, and no change or even an opposite behavior in
EGR1þ cells (Figure 6). In particular, seven genes were
upregulated by EGR1 transduction and remained significantly
upregulated despite the treatment with TK inhibitor, suggesting
direct and robust regulation by this transcription factor (that is,
TFF2, PPDPF, AGR2 and CCL5; Supplementary Figure 8).
DISCUSSION
The discovery of specific genetic lesions in lung cancer patients
has profoundly changed their clinical management. Kinases are
now recognized as critical tumorigenic events in human cancer.
Constitutively active receptor and non-RTKs are excellent exam-
ples for the development of modern ‘patient-specific’ and/or
‘tumor-restricted’ therapies.36 However, clinical responses are
heterogeneous as a result of multiple mechanisms of resistance.
It is believed that multi-targeted drugs may be more appropriate
than highly restricted inhibitors. In NSCLC patients, ALK is a
powerful driver/oncogene;37 nevertheless, crizotinib, a dual
ALK/Met inhibitor, is successful only in a subset of ALKþ
patients (B60%). Moreover, responder patients inevitably
become refractory.38 Thus, the different responses to ALKi may
underlie intrinsic mechanisms that undermine ‘ab initio’ their
efficacy and/or favor the occurrence of resistance. Their
identification provide the basis for a molecular stratification of
ALKþ NSCLC patients and drive the selection of more compliant
treatments.21,39
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Here we studied the level of ALK oncogenic addiction of human
ALKþ NSCLC and the cooperative role of several kinases. We
show that the different responses of NSCLC cell lines to ALK are
dependent on the activation of alternative pathways in which
wild-type RTK can overcome ALK signaling blockade.
Using phosphoproteomics, different studies have demonstrated
that lung cancer cells and primary tumors express kinases able
to jointly participate to hierarchical networks or independently
signal through separate parallel pathways.5,40 Our previous
phosphomapping findings showed that ALK inhibition is rapidly
followed by the parallel activation/phosphorylation of several
other TKs (EGFR, Met, fibroblast growth factor receptor, Jak1 or
insulin-like growth factor receptor) in H2228 cells, but not in
H3122 cells, which are markedly ALK-addicted.30 Interestingly, the
dual inhibition with gefitinib or cetuximab overcomes this
resistance feedback loop and increases cell death. The elevated
levels of EGFR protein in H2228 compared with H3122, without
displaying any amplification or known mutation, might explain
their partial addiction to ALK and the better responsiveness to the
cotreatment. Notably, other members of the EGFR family, ERBB2
and ERBB3, can also overcome the partial resistance to ALKi, as the
combination with lapatinib and an ALKi markedly reduced ERBB2
phosphorylation and cell viability. This suggests that forced EGFR
family signaling (EGFR and ERBB2), even in naive/untreated NSCLC
cells, may be critical, similar to what has been recently described
for the acquired resistance to ALKi.20,41 Nevertheless, we
demonstrated that this occurs in a context of wild-type EGFR
and non-mutated ALK and, more importantly, in absence of drug
selection.17,42 Our studies are in line with those described by
Prahallad et al.43, which have documented an intrinsic resistance
to vemurafenib caused by a feedback activation of EGFR
signaling in BRAF (V600E) mutant colon cancer cells. Thus, EGFR
members can elicit an undermining mechanism that sustains the
partial resistance seen in some ALKþ NSCLC patients, or
2424
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Figure 6. EGR1 overexpression regulates the transcription of genes independently of ALK inhibition. (a) Heat map of gene expression
signature in response to ALK and/or EGFR inhibition in H2228 cells and in H2228 cells overexpressing EGR1. The color scale bar represents
relative gene expression changes calculated as log2 (inhibited/non-inhibited). (b) List and expression changes of genes up- or
downregualated by the overexpression of EGR1 independently of ALK or EGFR inhibition.
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ultimately post-therapy resistance to ALKi.41 A greater complexity
is provided by the observation that the engagement of wild-type
EGFR or wild-type MET receptors could also restore cell viability of
H2228 and H3122 cells via EGR1 and/or Erk1/2 and Akt
activation.32 Remarkably, in H2228 the effects of HGF on cell
survival were less significant, more likely for the partial
dependence of these cells on EGFR signaling. We believe that
EGFR member family expression levels or phosphorylation should
be determined at diagnosis in order to benefit the most on
combined therapies.
As cancer cells often trigger alternative pathways to bypass
specific RTK inhibition, we further dissected other signaling
pathways to find a common node of ALK and other RTKs.
In ALKþ NSCLC cells, Src kinase represents a suitable target as
in ALKþ anaplastic lymphoma its ablation has relevant effects in
analogy to many human cancers.35 In H2228 cells, Src inhibitors
alone or in combination with ALKi increased the percentage of
apoptotic cells similarly to ALK and gefitinib, suggesting that Src
mediates ALK and EGFR signaling in NSCLC. These data are
consistent with the notion that ALK and EGFR pathways
functionally compensate each other. Nevertheless, other
alternative signaling pathways might be operational in H2228,
as EGF partially recovered cells from death. Indeed, rescue by EGF
in H3122 was completely abrogated upon ALK and Src inhibition,
suggesting that EGF/EGFR signaling triggers prosurvival responses
through Src.
Next, to define additional putative downstream ‘culprits’, we
used gene expression profiling analyses, which showed the EGR1
gene as a key regulator. The cotreatment with ALKi and gefitinib
downregulated the expression of a single transcript, EGR1. EGR1 is
a transcription factor, known to have a polyhedric/versatile role in
human cancers,44 engaged in proapoptotic or prosurvival signals,
depending on the cellular context.45 In solid tumors, including
lung cancers, EGR1 is a downstream target of EGFR through the
mitogen-activated protein kinase signaling pathways.46 Indeed, its
overexpression, able to sustain cell viability in presence of ALK and
EGFR inhibitors, was characterized by well-defined transcriptional
signature. Among the upregulated genes, TFF2 (trefoil factor 2)
and AGR2 (anterior gradient 2) seem to be relevant, as in
human cancers they contribute to tumor growth, resistance to
apoptosis and cell migration.47,48 Thus, EGR1 could represent an
ideal target for the design and implementation of new therapeutic
approaches in ALK-positive NSCLC.
Our data indicate that the molecular characterization of primary
lung cancers is required to foresee whether any given therapeutic
protocol may be successful. The genetic heterogeneity of lung
tumors implies that parallel pathways or different mechanisms of
resistance may coexist ‘ab initio’ and that targeting a single
molecule might be ineffective. This stratification is necessary to
develop new combined treatment for NSCLC patients. Targeting
common molecules downstream of RTKs, such as EGR1 or Src,
could bypass intrinsic or acquired drug resistance derived from
the treatment with a single RTK inhibitor. Our data support the
idea that the development of less-restricted drugs or the design of
new therapeutic protocols making use of multiple TK inhibition
might be more efficacious, even for the first-line treatment of
NSCLC.
MATERIALS AND METHODS
Cell cultures, inhibitors and growth factors
Human lung cancer EML4–ALK-positive cell lines, H2228 (var 2: EML4/es6–
ALK/es20) and H3122 (var 1: EML4/es13–ALK/es20), were grown in RPMI
medium (Lonza, Basel, Switzerland) with 10% fetal calf serum (FCS). Human
HEK-293T cells were cultured in Dulbecco’s modified Eagle’s medium with
10% FCS. Human immortalized airway epithelial cells (NuLi-1) were grown
in bronchial epithelial cell basal medium (Lonza) with 10% FCS on human
collagen type-VI-coated plates (Sigma, St Louis, MO, USA).
ALK inhibitors, CEP-14083, CEP-26939 and CEP-28122 (Cephalon), were
used at 300 nM/l; gefitinib (ZD1839, Iressa) at 1 mM/l; lapatinib at 2 mM/l; Src
kinase inhibitor-1 (Calbiochem, Millipore Corporation, Billerica, MA, USA) at
5mM/l; and PHA-665752 (Met inhibitor) at 250nM. EGF was used at 10ng/ml,
Heregulin was used at 20ng/ml, and HGF (Sigma) was used at 50ng/ml.
Cell proliferation, cell cycle analysis, cell apoptosis and clonogenic
assays
In 24-well plates, 8 104 cells/ml were grown in duplicates. The treatment
with kinase inhibitors or with growth factors was done every 24 h in 0.05%
FCS. Cell growth was analyzed using Cell Titer-GloMax assay (Promega,
Fitchburg, WI, USA). For cell cycle analysis, cells were fixed for 1 h in 70%
ethanol at 4 1C. After washing, cells were treated with RNase (0.25mg/ml)
and stained with propidium iodide (50mg/ml). The sub-G0-phase fraction
was calculated using the Modfit program from Becton-Dickinson (San Jose,
CA, USA). Apoptosis was measured by flow cytometry after staining with
the mitochondrion-permeable voltage sensitive dye tetrametylrodamine
methyl ester and fluorescence-activated cell sorting analysis. Clonogenic
assay, were performed as described.28
DNA constructs
EGR1 cDNA in pCMV-Sport6 was purchased from ImaGenes GmbH (Berlin,
Germany). EGR1 cDNA was then subcloned into the lentiviral vector pWPI
for lentivirus production. pCMV-Sport6 containing EGR1 construct was
digested to obtain a EcoRV/NotI fragment, blunted with Klenow enzyme
(Roche, Basilea, Switzerland) and cloned into the PmeI site of the lentiviral
vector pWPI.
Lentivirus and short hairpin RNA production, cell infection and cell
sorting
Lentivirus particles were obtained as described.27 For cell sorting
enrichments, EGFP-positive cells were sorted using a MoFlo High-
Performance instrument (DAKO Cytomation, Glostrup, Denmark) and
EGFP expression was checked by flow cytometry over time.
Cell lysis and western blot analysis
H3122 and H2228 were plated on six-well plates and treated with specific
kinase inhibitors in Dulbecco’s modified Eagle’s medium with 0.05% FCS.
Cells were lysed with GST-FISH (10mM MgCl2, 150mM NaCl, 1% NP40, 2%
Glycerol, 1mM EDTA, 25mM HEPES (pH 7.5)) buffer supplemented with
protease inhibitors (NaF, phenylmethanesulfonylfluoride, PIC and Na3VO4)
by scraping. The list of the antibodies is provided in Supplementary
Information.
RNA extraction, cDNA synthesis and reverse transcription–PCR
Total RNA was isolated from cells with TRIZOL lysis solution (Invitrogen, Life
Technologies Ltd, Paisley, UK). One microgram of total RNA was treated
with 5U/ml of DNase I recombinant RNase free (Roche) and it was
subjected to reverse transcription with SuperScript III reverse transcriptase
(Invitrogen). The cDNA obtained was subjected to PCR using specific
primers for PBGD, B2M and ABL as control of cDNA quality.
cDNA microarray and analysis
Total RNA was extracted using the TRIZOL reagent (Invitrogen) and
purified using the RNeasy total RNA Isolation Kit (Qiagen, Hilden,
Germany). RNA integrity was verified by means of a Bioanalyzer 2100
(Agilent Technologies, Santa Clara, CA, USA). Hybridization was performed
on HumanWG-12v4 BeadChips (Illumina, San Diego, CA, USA), using
biological triplicates for each condition. cDNA and biotinylated cRNA were
generated by Illumina TotalPrep RNA Amplification Kit (Ambion, Life
Technologies Ltd, Paisley, UK). Data were processed with the Illumina
GenomeStudio software using the following thresholds for significant
differential expression: ‘Illumina Custom’ test P-value o0.001, fold-change
42. Gene expression data were clustered and visualized with the GEDAS
software.29
Real-time quantitative PCR
cDNA was transcribed using SuperSCRIPT III following the manufacturer’s
instructions (Invitrogen). Quantitative reverse transcription–PCR was
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performed in triplicate on ICycler iQ Real-Time PCR Detection System (Bio-
Rad Laboratories, Hercules, CA, USA) with SYBR green dye.
Immunofluorescence and immunohistochemistry
Cells were grown for 12 h on glass coverlips, fixed in phosphate-buffered
saline containing 4% paraformaldehyde at room temperature (10min), and
then permeabilized with phosphate-buffered saline containing 0.3% Triton
X-100 for 5min. Anti-EGFR (1:100, Cell Signaling Technology, Danvers, MA,
USA), ERBB2 (1:300, Dako) and ERBB3 (1:100, LabVision, ThermoScientific,
Kalamazoo, MI, USA) were incubated O/N, and heterodimer formation was
detected using DUOLINK II assay (Olink Bioscience, Uppsala, Sweden).
Images were acquired by Imager.Z1 fluorescent microscope (Zeiss) and
analysed with the Isis and Metaphor software. Immunohistochemistry was
performed on a semi-automated immunostainer as described previously.30
The following antibodies were used: anti-ALK (clone D5F3; Cell Signaling
Technology) and anti-ERBB2 (clone CB11; Novocastra, Leica, Milano, Italy).
Mice and in vivo bioluminescence experiments
CB/17 scid and NOD-SCID mice (Charles River Laboratories Italia S.p.A.,
Wilmington, DE, USA) were inoculated subcutaneously in both flanks
(single-cell suspension 1 107 in 0.2ml phosphate-buffered saline). Mice
were treated twice a day with 100mg/kg of Comp-2. Tumor growth was
measured over time. For imaging studies, luciferase-positive cell xenografts
were analyzed in vivo by IVIS100 (Xenogen, Grantham, Lincolnshire, UK)
instrument after intraperitoneal injection with D-luciferin (10ml/g body
weight, 15mg/ml). Mice were handled and treated in accordance with the
European Community guidelines.
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